CLINICAL TRIALS PROFILE FOR LUMIFY
✉ Email this page to a colleague
All Clinical Trials for LUMIFY
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03782701 ↗ | The Effect of Lumify™ Eyedrops on Eyelid Position | Completed | University of Miami | Phase 4 | 2019-06-18 | The purpose of the research is to see if Lumify™ has an effect on eyelid position. |
| NCT03782701 ↗ | The Effect of Lumify™ Eyedrops on Eyelid Position | Completed | Wendy Lee | Phase 4 | 2019-06-18 | The purpose of the research is to see if Lumify™ has an effect on eyelid position. |
| NCT04007276 ↗ | The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients | Not yet recruiting | Tulane University | Phase 4 | 2025-11-10 | Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops. |
| NCT04024891 ↗ | Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis | Completed | Ocuphire Pharma, Inc. | Phase 2 | 2019-08-13 | The objectives of this study are: - To evaluate the efficacy of Nyxol (phentolamine mesylate ophthalmic solution 1%) to expedite the reversal of pharmacologic mydriasis - To evaluate the safety of Nyxol - To evaluate the effect of Lumify® to suppress conjunctival hyperemia (redness) potentially associated with administration of Nyxol |
| NCT04683159 ↗ | Brimonidine Tartrate for Pterygium Surgery | Not yet recruiting | Uptown Eye Specialists | N/A | 2021-02-01 | Pterygium excision and conjunctival autograft surgery is commonly done to treat pterygiums. Excessive bleeding during the procedure creates a challenging operating field, prolongs surgery time, and prolongs healing. Brimonidine tartrate has a vasoconstrictive effect, which helps to reduce the amount of blood flow and hyperemia to the eye. Preoperative use of brimonidine has been shown to decrease subconjunctival hemorrhage during procedures such as cataract surgery, laser assisted in situ keratomileusis, strabismus surgery, and intravitreal injections. The focus of this study is to assess the effect of preoperative application of brimonidine tartrate 0.15% (Alphagan) and 0.025% (Lumify) on reducing hemorrhage during pterygium excision and conjunctival autograft surgery. |
| NCT05360784 ↗ | A Multi-Center, Double-Masked, Randomized, Active-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Preservative-Free Formulation With Lumify® 0.025% in Adult Subjects With Ocular | Not yet recruiting | Bausch & Lomb Incorporated | Phase 3 | 2022-05-01 | This is a multi-center, double-masked, randomized, active-controlled, parallel-group, efficacy and safety study that will enroll 386 participants at up to six clinical sites. Participants with ocular redness will be randomized to receive either brimonidine tartrate ophthalmic solution 0.025%, preservative-free formulation, or Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will be treated with study drug for approximately 4 weeks. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LUMIFY
Condition Name
Clinical Trial Locations for LUMIFY
Trials by Country
Clinical Trial Progress for LUMIFY
Clinical Trial Phase
Clinical Trial Sponsors for LUMIFY
Sponsor Name
